Find out what it's like to work at Geron and learn more about our job opportunities.

Visit Working with Us

 
 

Geron Company Overview

Geron is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

The discovery and early development of imetelstat, our sole product candidate, was based on our core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation.

Imetelstat is a potent and specific inhibitor of telomerase. Using our proprietary nucleic acid chemistry, we designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. We developed imetelstat from inception, and imetelstat has patent coverage extending through 2025.

Based on the data from our Phase 2 clinical trial evaluating imetelstat in essential thrombocythemia (ET), which showed durable hematologic and molecular responses in patients, and preliminary data from the first two cohorts of a pilot study in myelofibrosis (MF), we intend to develop imetelstat, in collaboration with our partner Janssen Biotech, Inc., to treat one or more hematologic malignancies such as MF, myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).

Find out what it's like to work at Geron and learn more about our job opportunities.

Visit Working with Us

Close
Form content here please :)